HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.

MLA

Loosli, Tom, et al. “HIV-1 Drug Resistance in People on Dolutegravir-Based Antiretroviral Therapy: A Collaborative Cohort Analysis.” The Lancet. HIV, vol. 10, no. 11, Nov. 2023, pp. e733–41. EBSCOhost, https://doi.org/10.1016/S2352-3018(23)00228-X.

APA

Loosli, T., Hossmann, S., Ingle, S. M., Okhai, H., Kusejko, K., Mouton, J., Bellecave, P., van Sighem, A., Stecher, M., d’Arminio Monforte, A., Gill, M. J., Sabin, C. A., Maartens, G., Günthard, H. F., Sterne, J. A. C., Lessells, R., Egger, M., & Kouyos, R. D. (2023). HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. The Lancet. HIV, 10(11), e733–e741. https://doi.org/10.1016/S2352-3018(23)00228-X

Chicago

Loosli, Tom, Stefanie Hossmann, Suzanne M Ingle, Hajra Okhai, Katharina Kusejko, Johannes Mouton, Pantxika Bellecave, et al. 2023. “HIV-1 Drug Resistance in People on Dolutegravir-Based Antiretroviral Therapy: A Collaborative Cohort Analysis.” The Lancet. HIV 10 (11): e733–41. doi:10.1016/S2352-3018(23)00228-X.